Hennigsdorf, Germany – April 16, 2025 – Pantherna Therapeutics GmbH, a company specializing in advanced LNP technologies for mRNA-based therapeutics, today announced the grant of Japanese Patent JP2021533821 by the Japan Patent Office (JPO).

Effective April 16th, the patent, titled “Recombinant nucleic acid construct”, protects a key innovation involving the company’s proprietary PTXmRNA® technology and its defined regulatory untranslated regions (5´- /3´- UTRs).

Extensive in vitro and in vivo evidence strongly support PTXmRNA’s effective and useful application across all tissues and cell types, underscoring the strength and versatility of this technology.

Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, commented on the recent patent approval: “We welcome the Japanese Patent Office’s recognition of our commitment to innovation. This patent further solidifies our standing within Japan, a key market for biotech innovation, and enhances our ability to pursue strategic partnerships and licensing opportunities in the mRNA therapeutics landscape.”